Latest News and Press Releases

Strengthened financial position resulting from recently announced MARGENZA® transaction and previously announced receipt of milestone payment from Incyte related to advancement of ZYNYZ®ADAM9-directed...

Houston biotech awarded $4.7MM in homegrown Texas support for new technology to safely improve the treatment of advanced blood cancers and genetic diseases

Cascade Announces Poster Presentation at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Der Start der zulassungsrelevanten Phase-3-Studie für nicht-kleinzelliges Lungenkarzinom ist ein wichtiger erster Schritt in BioNTechs und OncoC4s strategischer Kollaboration, die im März 2023...

 Initiation of pivotal Phase 3 trial in non-small cell lung cancer (NSCLC) marks the first landmark in BioNTech’s and OncoC4’s strategic collaboration initiated in March 2023 with the aim to evaluate...

BNT316/ONC-392 ist ein innovativer monoklonaler anti-CTLA-4-Antikörperkandidat, der gemeinsam von BioNTech und OncoC4 als Mono- oder Kombinationstherapie zur Behandlung verschiedener solider...

BNT316/ONC-392 is a next-generation anti-CTLA-4 monoclonal antibody candidate jointly developed by BioNTech and OncoC4 as monotherapy or combination therapy in a range of solid tumor indications,...

- Clinical data for wholly-owned anti-CTLA-4 franchise show best-in-class safety profiles for unmasked and masked candidates, unlocking the full therapeutic benefit of anti-CTLA-4 in combination with...

BioNTech erhält weltweite Exklusivlizenz von OncoC4 für die Entwicklung und Kommerzialisierung des monoklonalen Anti-CTLA-4-Antikörperkandidaten ONC-392BioNTech und OncoC4 werden gemeinsame...

BioNTech to receive exclusive worldwide license from OncoC4 to develop and commercialize its anti-CTLA-4 monoclonal antibody candidate, ONC-392BioNTech and OncoC4 will co-develop ONC-392 as...